Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Cash from Discontinued Operations (2021 - 2022)

Theravance Biopharma (TBPH) has disclosed Cash from Discontinued Operations for 2 consecutive years, with 178968000.0 as the latest value for Q4 2022.

  • Quarterly Cash from Discontinued Operations fell 6455.4% to 178968000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was 184566000.0 through Dec 2022, changed N/A year-over-year, with the annual reading at 184566000.0 for FY2022, 761.12% down from the prior year.
  • Cash from Discontinued Operations for Q4 2022 was 178968000.0 at Theravance Biopharma, down from 5209000.0 in the prior quarter.
  • The five-year high for Cash from Discontinued Operations was 2816000.0 in Q4 2021, with the low at 178968000.0 in Q4 2022.